醒脑静联合丹参注射液治疗高血压性脑出血47例疗效评价

Clinical efficacy of Xingnaojing injection combined with Danshen injection in non-operative treatment of 47 patients with hypertensive cerebral hemorrhage

目的探讨醒脑静联合丹参注射液治疗高血压性脑出血的临床疗效。方法将2011年8月—2012年12月本院收治的90例高血压性脑出血患者随机分为治疗组(n=47)与对照组(n=43),2组在对症治疗基础上静脉滴注复方丹参注射液20 mL/d,治疗组加用醒脑静注射液20 mL/d,14 d为一个疗程。记录并比较治疗3、7、14 d后的血肿、脑水肿吸收情况及临床疗效。结果 2组治疗后血肿均较同组入院前明显缩小,且治疗组治疗7、14 d后的血肿体积明显小于对照组(P<0.05);治疗14 d后,治疗组脑水肿吸收总体有效率为87.2%,显效率达51.1%,均明显高于对照组的74.4%和32.6%,但差异无统计学意义(P>0.05);治疗14 d后,治疗组神经功能缺损评分明显低于对照组(P<0.05),且总体有效率(91.5%)和治愈率(31.9%)均高于对照组的81.3%和20.9%,但差异无统计学意义(P>0.05);治疗组有4例(8.5%)患者出现轻微不良反应,2组各有1例患者病情恶化死亡。结论醒脑静联合丹参注射液辅助治疗高血压性脑出血疗效确切,能促进血肿与脑水肿吸收,联合用药能进一步减轻脑组织损伤。

Objective To observe the clinical efficacy of Xingnaojing injection combined with Danshen injection in nonoperative treatment of hypertensive cerebral hemorrhage. Methods Ninety cases with hypertensive cerebral hemorrhage hospitalized from Aug. 2011 to Dec. 2012 were randomized into treatment group （n = 47） and control group （n = 43）. Both groups were given Danshen injection 20 mL/d by intravenous infusion on the basis of symptematie treatment, based on which the treatment group was added with Xingnaojing injection 20 mL/d for a course （14 d）. Hematoma, brain edema absorption and clinical efficacy 3 ds, 7ds, 14ds after treatment were recorded and compared. Results After treatment, Hematoma significantly reduced, and hematoma volume of treatment group was significantly smaller than that of control group for 7 d （P 〈 0.05）. 14 d later, cerebral edema absorption of the treatment group whose overall efficiency （87.2 % ）, efficacy rat （51, 1% ） were higher than those of the control group （74.4%, 32.6% ）, there being no statistical difference （P 〉0.05）. Fourteen days later, neural function defect score of the treatment group was significantly lower than the control group （P 〈 0.05）, and overall efficiency （91.5 % ） and basic cure proportion （31.9%） were both higher than those of the control group （81.3%, 20. 9% ）, the difference having no statistical significance （P 〉0.05）. Four cases （8.5 % ） in the treatment group had mild adverse reactions, the rest with no significant adverse reactions. There was one death case in both groups. Conclusion The combined use of Xingnaojing and Danshen injection in treatment of hypertensive cerebral hemorrhage could cooperatively facilitate the absorption of hematoma and cerebral edema, also further reduce the injury of brain tissue.